| CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors RG Majzner, JL Theruvath, A Nellan, S Heitzeneder, Y Cui, CW Mount, ... Clinical Cancer Research 25 (8), 2560-2574, 2019 | 475 | 2019 |
| Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling EW Weber, KR Parker, E Sotillo, RC Lynn, H Anbunathan, J Lattin, ... Science 372 (6537), eaba1786, 2021 | 392 | 2021 |
| Tuning the antigen density requirement for CAR T-cell activity RG Majzner, SP Rietberg, E Sotillo, R Dong, VT Vachharajani, ... Cancer discovery 10 (5), 702-723, 2020 | 381 | 2020 |
| Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors J Theruvath, E Sotillo, CW Mount, CM Graef, A Delaidelli, S Heitzeneder, ... Nature medicine 26 (5), 712-719, 2020 | 215 | 2020 |
| Mannan-binding lectin deficiency—good news, bad news, doesn't matter? S Heitzeneder, M Seidel, E Förster-Waldl, A Heitger Clinical immunology 143 (1), 22-38, 2012 | 212 | 2012 |
| Identification of GPC2 as an oncoprotein and candidate immunotherapeutic target in high-risk neuroblastoma KR Bosse, P Raman, Z Zhu, M Lane, D Martinez, S Heitzeneder, KS Rathi, ... Cancer cell 32 (3), 295-309. e12, 2017 | 177 | 2017 |
| Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication J Theruvath, M Menard, BAH Smith, MH Linde, GL Coles, GN Dalton, ... Nature medicine 28 (2), 333-344, 2022 | 143 | 2022 |
| Harnessing the immunotherapy revolution for the treatment of childhood cancers RG Majzner, S Heitzeneder, CL Mackall Cancer cell 31 (4), 476-485, 2017 | 143 | 2017 |
| Enhanced safety and efficacy of protease-regulated CAR-T cell receptors L Labanieh, RG Majzner, D Klysz, E Sotillo, CJ Fisher, JG Vilches-Moure, ... Cell 185 (10), 1745-1763. e22, 2022 | 119 | 2022 |
| GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity S Heitzeneder, KR Bosse, Z Zhu, D Zhelev, RG Majzner, MT Radosevich, ... Cancer Cell 40 (1), 53-69. e9, 2022 | 102 | 2022 |
| Pregnancy-associated plasma protein-A (PAPP-A) in Ewing sarcoma: role in tumor growth and immune evasion S Heitzeneder, E Sotillo, JF Shern, S Sindiri, P Xu, R Jones, M Pollak, ... JNCI: Journal of the National Cancer Institute 111 (9), 970-982, 2019 | 53 | 2019 |
| Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 EW Weber, KR Parker, E Sotillo, RC Lynn, H Anbunathan, J Lattin, ... | 30 | 2021 |
| Engineered CD47 protects T cells for enhanced antitumour immunity SA Yamada-Hunter, J Theruvath, BJ McIntosh, KA Freitas, F Lin, ... Nature, 1-9, 2024 | 8 | 2024 |
| Abstract PR07: GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma … J Theruvath, B Smith, MH Linde, E Sotillo, S Heitzeneder, K Marjon, ... Cancer Research 80 (14_Supplement), PR07-PR07, 2020 | 5 | 2020 |
| Immu-07. checkpoint molecule B7-H3 is highly expressed on medulloblastoma and proves to be a promising candidate for car T cell immunotherapy J Theruvath, S Heitzeneder, R Majzner, CM Graef, K Cui, A Nellan, ... Neuro-Oncology 19 (Suppl 4), iv28, 2017 | 5 | 2017 |
| Mannan-binding lectin deficiency attenuates acute GvHD in pediatric hematopoietic stem cell transplantation S Heitzeneder, P Zeitlhofer, U Pötschger, E Nowak, MG Seidel, M Hölzl, ... Bone Marrow Transplantation 50 (8), 1127-1129, 2015 | 5 | 2015 |
| Anti-GD2 antibody disrupts GD2: Siglec-7 interactions and synergizes with CD47 blockade to mediate tumor eradication J Theruvath, M Menard, BAH Smith, MH Linde, GL Coles, W Wu, L Kiru, ... BioRxiv, 2021.03. 19.436221, 2021 | 3 | 2021 |
| GD2 is a macrophage checkpoint molecule and combined GD2/CD47 blockade results in synergistic effects and tumor clearance in xenograft models of neuroblastoma and osteosarcoma J Theruvath, B Smith, MH Linde, E Sotillo, S Heitzeneder, K Marjon, ... CANCER RESEARCH 80 (14), 35-35, 2020 | 3 | 2020 |
| 327 B7-H3 chimeric antigen receptor modified T cells show potent anti-tumor activity in a preclinical model of glioblastoma KHK Chow, S Heitzeneder, P Xu, J Theruvath, SS Mitra, SH Cheshier, ... Neurosurgery 64 (CN_suppl_1), 272, 2017 | 3 | 2017 |
| Pregnancy associated plasma protein A (PAPP-A) is a potential novel therapeutic target in Ewing sarcoma S Heitzeneder, JF Shern, J Khan, CL Mackall Cancer Research 76 (14_Supplement), 571-571, 2016 | 2 | 2016 |
